1. Eraso LH, Fukaya E, Mohler ER 3rd, et al. Peripheral arterial disease, prevalence and cumulative risk factor profile analysis. Eur J Prev Cardiol . 2014;21:704-711.
2. Pasternak RC, Criqui MH, Benjamin EJ, et al; American Heart Association. Atherosclerotic Vascular Disease Conference: Writing Group I: epidemiology. Circulation . 2004;109:2605-2612.
3. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA . 2001;286:1317-1324.
4. Olin JW, Sealove BA. Peripheral artery disease: current insight into the disease and its diagnosis and management. Mayo Clin Proc . 2010;85:678-692.
5. Andras A, Ferkert B. Screening for peripheral arterial disease. Cochrane Database Syst Rev . 2014;(4):CD010835.
6. Guirguis-Blake JM, Evans CV, Redmond N, et al. Screening for peripheral artery disease using ankle-brachial index: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA . 2018;320:184-196.
7. US Preventive Services Task Force. Screening for peripheral artery disease and cardiovascular disease risk assessment with ankle-brachial index: US Preventive Services Task Force recommendation statement. JAMA . 2018;230:177-183.
8. American Heart Association Writing Group 2. Atherosclerotic Peripheral Vascular Disease Symposium II: screening for atherosclerotic vascular diseases: should nationwide programs be instituted? Circulation . 2008;118:2830-2836.
9. Berger JS, Hochman J, Lobach I, et al. Modifiable risk factor burden and the prevalence of peripheral artery disease in different vascular territories. J Vasc Surg . 2013;58:673-681.
10. Joosten MM, Pai JK, Bertoia ML, et al. Associations between conventional cardiovascular risk factors and risk of peripheral artery disease in men. JAMA . 2012;308:1660-1667.
11. Carmelli D, Fabsitz RR, Swan GE, et al. Contribution of genetic and environmental influences to ankle-brachial blood pressure index in the NHLBI Twin Study. National Heart, Lung, and Blood Institute. Am J Epidemiol . 2000;151:452-458.
12. Aboyans V, Criqui MH, Denenberg JO, et al. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation . 2006;113:2623-2629.
13. Gerald-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation . 2017;135:e726-e779.
14. McDermott MM, Greenland P, Liu K, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA . 2001;286:1599-1606.
15. Cranley JJ. Ischemic rest pain. Arch Surg . 1969;98:187-188.
16. Khan NA, Rahim SA, Anand SS, et al. Does the clinical examination predict lower extremity peripheral arterial disease? JAMA . 2006;295:536-546.
17. Wennberg PW. Approach to the patient with peripheral arterial disease. Circulation . 2013;128:2241-2250.
18. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vas Endovasc Surg . 2007;33:S1-S75.
19. Armstrong EJ, Wu J, Singh GD, et al. Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peripheral artery disease. J Vasc Surg . 2014;60:1565-1571.
20. Lane R, Harwood A, Watson L, et al. Exercise for intermittent claudication. Cochrane Database Syst Rev . 2017;(12):CD000990.
21. Murphy TP, Cutlip DE, Regensteiner JG, et al; CLEVER Study Investigators. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation . 2012;125:130-139.
22. Fakhry F, Fokkenrood HJP, Pronk S, et al. Endovascular revascularization versus conservative management for intermittent claudication. Cochrane Database Syst Rev . 2018;(3):CD010512.
23. Hageman D, Fokkenrood HJ, Gommans LN, et al. Supervised exercise therapy versus home-based exercise therapy versus walking advice for intermittent claudication. Cochrane Database Syst Rev . 2018;(4):CD005263.
24. McDermott MM, Spring B, Berger JS, et al. Effect of a home-based exercise intervention of wearable technology and telephone coaching on walking performance in peripheral artery disease: the HONOR randomized clinical trial. JAMA . 2018;319:1665-1676.
25. Ruiz-Canela M, Estruch R, Corella D, et al. Association of Mediterranean diet with peripheral artery disease: the PREDIMED randomized trial. JAMA . 2014;311:415-417.
26. Zahradka P, Wright B, Weighell W, et al. Daily non-soy legume consumption reverses vascular impairment due to peripheral artery disease. Atherosclerosis . 2013;230:310-314.
27. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg . 2007;45:645-655.
28. Kumbhani DJ, Steg G, Cannon CP, et al. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J . 2014;35:2864-2872.
29. Wong PF, Chong LY, Mikhailidis DP, et al. Antiplatelet agents for intermittent claudication. Cochrane Database Syst Rev . 2011;(11):CD001272.
30. Critical Leg Ischaemia Prevention Study (CLIPS) Group, Catalano M, Born G, Peto R. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med . 2007;261:276-284.
31. Morley RL, Sharma A, Horsch AD, et al. Peripheral artery disease. BMJ . 2018;360:j5842.
32. Bedenis R, Stewart M, Cleanthis M, et al. Cilostazol for intermittent claudication. Cochrane Database Syst Rev . 2014;(10):CD003748.
" class="smart-paging drupal-content" src="/sites/all/modules/contrib/smart_paging/plugins/wysiwyg/smart_paging/images/spacer.gif" title="<--pagebreak-->">
33. Salhiyyah K, Forster R, Senanayake E, et al. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev . 2015;(9):CD005262.
34. Stewart M, Morling JR, Maxwell H. Padma 28 for intermittent claudication. Cochrane Database Syst Rev . 2016;(3):CD007371.
35. Kleijnen J, Mackerras D. Vitamin E for intermittent claudication. Cochrane Database Syst Rev . 1998;(1):CD000987.
36. Nicolai SPA, Kruidenior LM, Bendermacher BLW, et al. Ginkgo biloba for intermittent claudication. Cochrane Database Syst Rev . 2013;(6):CD006888.
37. Campbell A, Price J, Hiatt WR. Omega-3 fatty acids for intermittent claudication. Cochrane Database Syst Rev . 2013;(7):CD003833.
38. American Surgical Association, New York Surgical Society, Philadelphia Academy of Surgery, Southern Surgical Association (US), Central Surgical Association. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity: the STILE trial. Ann Surg . 1994;220:251-268.
39. Ouriel K, Veith FJ, Sasahara AA. Thrombolysis or peripheral arterial surgery: phase I results. TOPAS Investigators. J Vasc Surg . 1996;23:64-73.
40. Bradbury AW, Ruckley CV, Fowkes FGR, et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised, controlled trial. Lancet . 2005;366:1925-1934.
41. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med . 1992;326:381-386.
